-
Article | 2017.08.07
Anti-Rabies Center - Rabies post-exposure prophylaxis
The Anti-Rabies Center-Rabies post-exposure prophylaxis-attends to anyone who has been in contact with an animal that may transmit rabies, either in France or abroad. Rabies is a deadly disease and treatment needs to be started as soon as possible. The medical team will see any patients at risk, immediately following rabies exposure, or wishing to continue a course of treatment started abroad.
-
Article | 2020.06.22
Deciphering the virus interactions with the entry receptors in human cells, and their potential inhibition
Aim: Researchers will develop and employ a workflow that combines cryogenic light and electron microscopy imaging modalities with computational analysis and data mining to determine high-resolution in-situ structural images of the virus-spike interactions with cell receptors and with the antibodies that abrogate their cell entry. These studies will provide a blueprint for the design of...
-
Article | 2020.08.20
Licensing opportunities
Available TechnologiesIf you are interested in currently available technologies from the Institut Pasteur in 4 main categories (Diagnostic, Therapeutics, Vaccines and Technology), please contact the Business Development teamContact us
-
Document de presse | 2022.07.22
Meningref trial shows better protection against meningococcal infection in hematopoietic stem cell transplant recipients
The team in the Hematology Department at Henri Mondor AP-HP Hospital, coordinated by Dr. Christine Robin, and scientists from the Institut Pasteur (the Invasive Bacterial Infections Unit led by Professor Muhamed-Kheir Taha) recently studied protection against meningococcal infection in patients who had received hematopoietic stem cell transplantation.The results of this trial (NCT03509051),...
-
News | 2024.03.25
Tackling flaviviruses and preparing the European Union for emerging threats
The genus flavivirus includes several human pathogens, such as Zika, dengue, West Nile virus (WNV) and yellow fever virus, which persist as major threats to global public health. Yellow4FLAVI, coordinated by Giovanna Barba-Spaeth, Institut Pasteur, comprises 13 partner institutions and is supported by the European Union with with € 8 million. The aim is to use the 17D yellow fever vaccine as...
-
Article | 2019.08.06
Vaccinology and Immunotherapy Initiative: Fundamental Research
Many different fields of the highly recognized fundamental research pursued at the Institut Pasteur are connected to vaccinology or immunotherapy. These include pathogen identification and characterization, structural analysis, in silico approaches, analysis of mechanisms to potentially enhance antigen immunogenicity and/or delivery or to identify specific immunotherapy targets, effects of...
-
Document de presse | 2006.10.25
Pertussis is still with us!
Whooping cough or pertussis is still the primary cause of death by bacterial infection in infants less than two months old, in France despite general vaccination. The endemicity of this infection is observed in many vaccinated countries. The agent of the disease, a bacterium, was isolated by the Pasteur scientist, Jules Bordet(1) in 1906. For this centenial, the Institut Pasteur is co-organising...
-
Fiche maladie | 2015.10.06
Whooping cough (pertussis)
Whooping cough, long thought of as a childhood illness, can be severe at any age. This bacterial infection is particularly dangerous, and sometimes even fatal, for unvaccinated or partially vaccinated infants and at-risk individuals such as pregnant women and elderly people.
-
News | 2024.11.25
Four New Pasteur Courses to Boost Your Expertise
The Institut Pasteur is offering four new specialized courses for professionals and students eager to expand their knowledge in critical areas of health science. With urgent global challenges such as climate change, emerging infectious diseases, and maternal and child health, these courses provide the expertise needed to address today’s most pressing issues.Explore key topics such as climate...
-
Document de presse | 2016.07.18
Malaria: a genetically attenuated parasite induces an effective, long-lasting immune response
With nearly 3.2 billion people currently at risk of contracting malaria, scientists from the Institut Pasteur, the CNRS and Inserm have experimentally developed a live, genetically attenuated vaccine for Plasmodium, the parasite responsible for the disease. By identifying and deleting one of the parasite's genes, the scientists enabled it to induce an effective, long-lasting immune response...